Parnell Pharmaceuticals Holdings Ltd

PARNF

AU0000XINEU9

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 11:07:19 2023-12-22 am EST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

2022	Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	CI
2021	DW Healthcare Partners V, L.P. managed by DW Healthcare Partners completed the acquisition of a 29% stake in Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $2.5 million	CI

Parnell Pharmaceuticals Holdings Ltd. announced that it has received $0.61 million in funding from Lincoln Park Capital

March 02, 2016

On March 3, 2016, Parnell Pharmaceuticals Holdings Ltd. closed the transaction.

Latest news about Parnell Pharmaceuticals Holdings Ltd

Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-20	CI
DW Healthcare Partners V, L.P. managed by DW Healthcare Partners completed the acquisition of a 29% stake in Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $2.5 million	21-01-27	CI
DW Healthcare Partners V, L.P. managed by DW Healthcare Partners made an offer to acquire Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARN.F) for $7.2 million.	20-12-20	CI
Parnell Pharmaceuticals Announces Nomovid Antiviral Nasal Spray	20-09-23	CI
Parnell Pharmaceuticals Holdings Ltd Reports Earnings Results for the Half Year Ended June 30, 2019	19-10-13	CI
Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Full Year Ended 31 December 2018; Provides Earnings Guidance for the Year 2019	19-04-04	CI
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2018; Revises Revenue Guidance for the Year 2018	18-11-02	CI
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018; Revised Earnings Guidance for the Full Year 2018	18-08-03	CI
Parnell Pharmaceuticals Holdings Ltd Reports Audited Earnings Results for the First Quarter Ended March 31, 2018; Revises Earnings Guidance for the Year 2018	18-04-28	CI
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017; Provides Earnings Guidance for the Year 2017	17-08-17	CI
Certain Ordinary Shares of Parnell Pharmaceuticals Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2017.	17-03-29	CI
Certain Options of Parnell Pharmaceuticals Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2017.	17-03-29	CI
Certain Warrants of Parnell Pharmaceuticals Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2017.	17-03-29	CI
Parnell Pharmaceuticals Holdings Ltd. Announces Consolidated Earnings Results for the Year Ended December 31, 2016; Provides Earnings Guidance for the Year 2017	17-03-21	CI
Parnell Pharmaceuticals Holdings Ltd will Change its Ticker to PARNF from PARN	17-01-04	CI
Parnell Pharmaceuticals Holdings Ltd(OTCPK:PARN.F) dropped from NASDAQ Composite Index	17-01-02	CI
Parnell Pharmaceuticals Holdings Ltd Announces $20 Million Secured Term Loan Facility	16-11-22	CI
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2016; Provides Revenue Guidance for the Full Year 2016 and 2017	16-11-02	CI
Parnell Pharmaceuticals Holdings Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016; Provides Revenue Guidance for the Year 2016	16-08-04	CI
Parnell Pharmaceuticals Holdings Ltd Announces Contract Manufacturing Agreement with Merial	16-05-31	CI
Parnell Pharmaceuticals Holdings Ltd. Announces Sales Results for the First Quarter of 2016; Reiterates Revenue Guidance for the Full Year of 2016	16-04-21	CI
Parnell Pharmaceuticals Holdings Ltd. announced that it has received $0.61 million in funding from Lincoln Park Capital	16-03-02	CI
Parnell Pharmaceuticals Holdings Ltd. Announces Consolidated Earnings Results for the Year Ended December 31, 2015; Provides Revenue Guidance for the Year 2016	16-02-23	CI
Parnell Pharmaceuticals Holdings Ltd. announced that it expects to receive $0.61 million in funding from Lincoln Park Capital	16-02-22	CI
Parnell Pharmaceuticals Holdings Ltd. announced that it expects to receive $15 million in funding from Lincoln Park Capital	16-01-10	CI

Chart Parnell Pharmaceuticals Holdings Ltd

Duration

Period

Chart Parnell Pharmaceuticals Holdings Ltd

More charts

Parnell Pharmaceuticals Holdings Ltd is an Australia-based company, which is engaged in offering the global veterinary pharmaceutical business marketing products in 14 countries. The Company operates sterile manufacturing facilities and offers digital technology platforms that integrate with the Companyâs products to offer veterinarians and animal owners superior solutions for their animal health needs. The Company also provides a fully integrated animal health platform. The Companyâs mySYNCH is a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. The Companyâs products include GONAbreed, estroPLAN, and RESPIRmycin. GONAbreed is used for the treatment of cystic ovaries and used in cattle synchronization protocols. The estroPLAN is used in animals with unobserved or non-detected estrus in cattle undergoing synchronization protocols. The RESPIRmycin is used for the treatment of respiratory disease in beef and non-lactating dairy cattle.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
PARNELL PHARMACEUTICALS HOLDINGS LTD	-.--%	29
ZOETIS INC.	-19.73%	72.39B
ELANCO ANIMAL HEALTH INCORPORATED	-11.01%	6.54B
BLUESTAR ADISSEO COMPANY	+15.88%	3.43B
VIMIAN GROUP AB	-0.68%	1.4B
JINYU BIO-TECHNOLOGY CO., LTD.	-17.27%	1.34B
VETOQUINOL SA	-2.73%	1.26B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-28.16%	1.2B
WUHAN KEQIAN BIOLOGY CO.,LTD	-14.67%	1.12B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-5.37%	990M